Here is a data-driven look at Divis Laboratories Ltd. (DIVISLAB), covering financial performance, valuation, and shareholding trends.
Divis Laboratories Revenue Trend
For FY2026, Divis Laboratories Ltd. recorded revenue of ₹10,560 Cr. That's 12.8% higher than the ₹9,360 Cr it brought in during FY2025.
Stepping back, the 10-year revenue CAGR of 10.8% tells a positive story. Divis Laboratories Ltd. has been growing at a solid clip.
With a top line of ₹10,560 Cr, Divis Laboratories Ltd. operates at a major scale within the pharmaceuticals sector.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹10,560 Cr | +12.8% |
| FY2025 | ₹9,360 Cr | +19.3% |
| FY2024 | ₹7,845 Cr | -3.3% |
| FY2023 | ₹8,112 Cr | -10.6% |
| FY2022 | ₹9,074 Cr | — |
View Divis Laboratories Ltd.'s full 10-year revenue trend with CAGR analysis →
Divis Laboratories Profitability
Year-over-year, net profit grew 17.2% from ₹2,191 Cr to ₹2,568 Cr in FY2026 for Divis Laboratories Ltd..
Margins moved in the right direction, with net margin rising to 24.3% from 23.4%.
Looking at per-share numbers, diluted EPS was ₹96.75 in FY2026 — up from ₹82.53.
Is Divis Laboratories Undervalued
Divis Laboratories Ltd. shares are currently trading at ₹8,585.00.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Divis Laboratories Shareholding Pattern
The promoter group has maintained its 51.9% holding through the last 4 quarters.
As of June 2026, FIIs own 20.2% of the company — up from 19.4% a year earlier.
As of June 2026, DIIs own 19.4% of the company — down from 19.8% a year earlier.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 51.9% | 20.2% | 19.4% | 8.5% |
| Mar 2026 | 51.9% | 20.3% | 19.2% | 8.6% |
| Dec 2025 | 51.9% | 20.1% | 19.3% | 8.8% |
| Sep 2025 | 51.9% | 19.4% | 19.8% | 9.0% |
Track quarterly shareholding changes for Divis Laboratories Ltd. →
Divis Laboratories Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹200.33B at the end of FY2026, up 18.3% from ₹169.32B a year earlier.
Property, Plant & Equipment is the largest block at 43.1%, followed by Inventories at 19.7% and Cash & ST Investments at 17.0%.
Equity makes up 83.7% of liabilities and equity, with debt at 0.0% and operating liabilities at 16.3%. Over the year, debt is up 75.0% and equity is up 12.0%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 34.14B |
| Receivables | 29.84B |
| Inventories | 39.54B |
| Property, Plant & Equipment | 86.28B |
| Investments | 690.00M |
| Intangibles & Goodwill | 60.00M |
| Other Assets | 9.78B |
| Category | Value |
|---|---|
| Equity | 167.61B |
| Short-term Debt | 20.00M |
| Long-term Debt | 50.00M |
| Trade Payables | 12.11B |
| Other Liabilities | 20.54B |
Divis Laboratories at a Glance
In summary, Divis Laboratories Ltd. (DIVISLAB) presents the following picture for fundamental analysts.
Revenue of ₹10,560 Cr in FY2026, up 12.8% year-over-year.
Long-term revenue has been compounding at 10.8% annually over 10 years.
The company is profitable, with a net margin of 24.3% and net income of ₹2,568 Cr.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Divis Laboratories Ltd.'s detailed profile on Craytheon.